filings.toolsItem 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
2K characters. Original on sec.gov · Markdown
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Information with respect to security ownership of certain beneficial owners and management is incorporated by reference from the discussion under the heading “Stock Ownership Information” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 24, 2022.
Equity Compensation Plan Information
The following table summarizes information about the options, warrants and rights and other equity compensation under the Company’s equity compensation plans as of the close of business on December 31, 2021. The table does not include information about tax qualified plans such as the Merck U.S. Savings Plan.
| Plan Category | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | Weighted-average exercise price of outstanding options, warrants and rights (b) | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) | |||||||||||||||||
| Equity compensation plans approved by security holders*(1)* | 18,572,010*(2)* | $ | 65.27 | 92,994,903 | ||||||||||||||||
| Equity compensation plans not approved by security holders | — | — | — | |||||||||||||||||
| Total | 18,572,010 | $ | 65.27 | 92,994,903 |
*(1)*Includes options to purchase shares of Company Common Stock and other rights under the following shareholder-approved plans: the Merck & Co., Inc. 2010 and 2019 Incentive Stock Plans, and the Merck & Co., Inc. 2010 Non-Employee Directors Stock Option Plan.
*(2)*Excludes approximately 11,790,206 shares of restricted stock units and 1,965,983 performance share units (assuming maximum payouts) under the Merck Sharp & Dohme 2010 and 2019 Incentive Stock Plans. Also excludes 193,107 shares of phantom stock deferred under the MSD Employee Deferral Program and 468,633 shares of phantom stock deferred under the Merck & Co., Inc. Plan for Deferred Payment of Directors’ Compensation.
Previous: Item 11. Executive Compensation. · Next: Item 13. Certain Relationships and Related Transactions, and Director Independence.